Navigation Links
Nearly 5 Million Doses of Nasal Swine Flu Vaccine Recalled
Date:12/23/2009

Tests reveal slight drop in potency, but not enough to require revaccination, FDA says,,

WEDNESDAY, Dec. 23 (HealthDay News) -- Nearly 5 million doses of a nasal spray version of swine flu vaccine have been recalled because the vaccine loses some potency over time, but not enough to diminish its protective effect, U.S. health officials announced Tuesday.

The recall involves more than 4.6 million doses of vaccine produced by drug maker MedImmune. Most of the doses have already been used, according to the U.S. Food and Drug Administration, which added that the vaccine was strong enough when it was distributed in October and November.

Pat El-Hinnawy, an FDA spokeswoman, said the action was a "voluntary, non-safety related recall. There are no safety concerns about the vaccine. The decrease in potency is not likely to be clinically significant. Individuals who received doses from the recalled lots do not need to be revaccinated."

The recall is the second swine flu vaccine recall this month prompted by a decline in potency. Manufacturer Sanofi Pasteur recalled nearly 800,000 children's doses of injectable H1N1 swine flu vaccine because tests showed they had lost some protective effect, but not enough to require revaccination.

On Tuesday, a top U.S. health official reported that the number of cases of H1N1 swine flu infection continues to decrease and the vaccine supply is now plentiful, but too few Americans are getting inoculated.

"The H1N1 vaccine supply is getting better and better," Dr. Anne Schuchat, director of the U.S. Centers for Disease Control and Prevention's National Center for Immunization and Respiratory Diseases, said during an afternoon press conference.

While cases of swine flu infection continue to diminish around the country, the H1N1 virus is still the dominant flu strain, Schuchat said. "Disease is at a better state around the country, less virus is circulating," she said. "But still everything we are seeing in terms of the flu strains is the H1N1 virus. So it's not gone at all."

There's no way to predict whether there will be a resurgence of swine flu, which peaked nationwide in early November with 48 states reporting widespread activity.

So, "it is important to not become complacent about the ongoing risk of H1N1 influenza," Schuchat stated.

Schuchat said an estimated 111 million doses of H1N1 vaccine have been distributed so far. A CDC survey done two weeks ago found that about 46 million people had received the vaccine, with approximately 40 percent of the doses going to children, she said.

"Coverage was about twice as high in children as it was in adults," she said. "That's really good news because usually with seasonal flu there's a lot more vaccination of adults, including seniors, than children. But with the H1N1 vaccine we were targeting children because they have been so hard hit by the virus."

Unlike seasonal flu, which typically poses a much bigger threat to people aged 65 and older, the swine flu has been targeting children and young adults, probably because they have little or no immunity to the H1N1 virus, which was last seen on a pandemic level more than 50 years ago.

In a possible response to the drop in swine flu cases nationwide, a new Harvard poll found that only 40 percent of those surveyed were concerned that they or their family would come down with the flu. In a September poll, 52 percent were worried.

The poll also found that by Dec. 17, about 56 million people -- more likely children than adults -- had received the H1N1 vaccine.

"Taking those two data points together, we think right now probably at least 60 million people have been vaccinated with the H1N1 vaccine," Schuchat said.

Now is a good time to get vaccinated against the H1N1 flu, she said, because supplies are plentiful. And should there be another wave of illness, you'd be protected.

Schuchat also said that children under 10 years of age should get two doses of the vaccine to be fully protected. A recent article in the Journal of the American Medical Association suggested that children might need only one dose.

"If you have children who are under 10 years of age that have gotten the H1N1 vaccine, it is important to know that your child needs a second dose," she said. "We recommend two doses of H1N1 vaccine about one month apart."

According to CDC estimates, children and young adults continue to be most vulnerable to the H1N1 flu. From mid-April, when the virus first surfaced, until November, 47 million Americans came down with the swine flu. About 16 million of those people were children under 18 years of age, and about 27 million were adults between 18 and 64.

During the same period, an estimated 9,820 people died, including 1,090 children aged 17 and younger, as well as 7,450 people aged 18 to 64, according to the CDC.

More information

For more on H1N1 swine flu, visit the U.S. Department of Health and Human Services.



SOURCES: Pat El-Hinnawy, public affairs officer, U.S. Food and Drug Administration; Dec. 22, 2009, teleconference with Anne Schuchat, M.D., director, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, Atlanta


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. ReBuilder Medical Technologies, Inc. Reports Monthly Sales in 2007 Nearly Doubling Monthly Sales in 2006, Including Record Daily Sales in September 2007
2. Nearly 30 Percent of Realtors(R) Lack Health Insurance
3. New Poll Finds Nearly Seven in 10 New Jersey Voters Support Smoke-Free Casinos
4. New Pharmaceutical Sales Force Communication Metrics: Nearly 6 Weeks of Sales Time per Rep Wasted Each Year
5. Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone Generated Global Sales of Nearly $5 Billion in the First Nine Months of 2007
6. K-State Researchers Predict That an Outbreak of Foot-And-Mouth Disease Could Cost Kansas Nearly a Billion Dollars
7. Smokers Cost Medicaid System Nearly $10 Billion
8. Research Indicates Nearly 25 Percent of Supplements Are Contaminated With Steroids, Stimulants and Banned Substances
9. Cipla Offers Modest AIDS Drug Price Cut: Not Nearly Enough, says AHF
10. Metabolic syndrome affects nearly 1 in 10 US teens
11. Eleven Florida Nonprofit Organizations to Receive Grants Totaling Nearly $1 Million From The Blue Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... 31, 2016 , ... More than 80 representatives of the Hepatitis B ... Cancer Foundation held an event on National Hepatitis Testing Day outside of Philadelphia City ... the leading cause of liver cancer. , Foundation leaders and the citywide coalition they ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... mix of advanced Artificial Intelligence (AI) and the latest in Clinical Patient ... center is integrating predictive analytic outputs directly into the clinical workflow. These insights ...
(Date:5/31/2016)... ... May 31, 2016 , ... Effective leaders not only drive service to the ... whole. On June 2, Northbound CEO Mike Neatherton and COO Paul Alexander will be ... opening plenary on “Leadership: The Journey to Authenticity” with Onsite Workshops CEO Miles Adcock ...
(Date:5/31/2016)... ... 31, 2016 , ... In his latest video, renowned AstroNumerologist ... humans. Using presidential candidate Donald Trump as an example, Kalsi describes the way ... not about adding numbers up,” says Kalsi. “It is about looking at each ...
(Date:5/31/2016)... ... 31, 2016 , ... TeaZa® Energy, LLC announces the launch of ... No Tobacco Day . The new flavor—Tropical TeaZa? Energy—will be available to customers ... , The new flavor is best described as a juicy, taste bud takeover. ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
Breaking Medicine Technology: